{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-003872","form_type":"8-K","ticker":"CABA","cik":"0001759138","company_name":"Cabaletta Bio, Inc.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.421583+00:00","generated_at":"2026-06-07T02:25:52.929488+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"FDA grants Fast Track to CABA-201 for dermatomyositis and systemic sclerosis; cash $241M","bullets":["FDA Fast Track Designations for CABA-201 in dermatomyositis (improve disease activity) and systemic sclerosis (improve organ dysfunction).","Unaudited cash, cash equivalents and short-term investments of $241M as of Dec 31, 2023; cash runway into first half of 2026.","Raised ~$94.1M in Q4 2023 via ATM program at avg $19.76/share (4.76M shares).","Anticipates initial Phase 1/2 data for SLE and myositis in H1 2024; for SSc and gMG in H2 2024.","Plans to file INDs for CABA-201 in additional autoimmune indications in 2024; combined US prevalence >1M patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-003872","json":"https://secwatch.observer/filing/0001193125-24-003872.json","markdown":"https://secwatch.observer/filing/0001193125-24-003872.md","text":"https://secwatch.observer/filing/0001193125-24-003872.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759138/000119312524003872/0001193125-24-003872-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759138/000119312524003872/d265299d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:25:52.929488+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}